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Heart failure (HF) is a worldwide phenomenon that affects millions 
of people yearly and carries a high mortality. It is estimated that 
37.7 million people worldwide are affected by HF.[1] The past three 
decades have seen a rise in research on HF. Large multicentre studies 
from the USA (e.g. ADHERE) and Europe (e.g. EHFS II) have 
provided greater insight into the aetiology, treatment and outcomes 
of patients with HF in the developed world.[2,3]
Observational studies from sub-Saharan Africa (SSA) show that 
hypertension, rheumatic valvular heart disease (RHD) and idiopathic 
cardiomyopathies are the main causes of HF affecting a young 
population.[4-6] This epidemiological pattern is strikingly different 
from that in the developed world, where a much older population 
suffers from HF, with ischaemic heart disease (IHD) the primary 
cause.[2,3] Despite these differences, the epidemiological transition 
is resulting in the rise of diabetes mellitus (DM), hypertension 
and IHD in SSA.[7,8] In 2008, communicable, maternal, perinatal 
and nutritional conditions accounted for the majority of deaths in 
South Africa (SA). However, of the non-communicable diseases, 
cardiovascular disease was the main cause of death.[9]
There is limited information on the use of evidence-based 
interventions and outcomes of HF in Africa. Contemporary 
epidemiological, aetiological and treatment information is needed 
in order to develop appropriate health policies for its diagnosis, 
management, prevention and control.[10,11]
Objective
To explore the treatment practices of doctors and outcomes of 
patients with congestive or acute heart failure (AHF) at Groote 
Schuur Hospital (GSH), a tertiary-level academic institution in Cape 
Town, SA, that serves as a referral hospital for 5 million people. The 
clinical features and causes of HF were also explored.
Methods
Study design and clinical setting
This was a sub-study of The Sub-Saharan Africa Survey of Heart 
Failure (THESUS-HF), a prospective, multicentre, observational 
survey of patients with AHF admitted to 12 university hospitals 
in nine countries.[5] The sub-study reported here is based on the 
enrolment of additional patients with AHF presenting to GSH and 
followed up in the existing THESUS-HF registry. Patients with 
AHF (incident (i.e. de novo) or prevalent (i.e. decompensation of 
previously diagnosed HF)) were added to the registry after the 
publication of the primary THESUS-HF article in 2012.[5]
Inclusion and exclusion criteria
The inclusion and exclusion criteria were the same as the criteria 
in the THESUS-HF study.[5] Briefly, patients aged >12 years with 
a diagnosis of AHF based on clinical evaluation and confirmed 
by echocardiography were enrolled. The exclusion criteria were 
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acute ST-elevation myocardial infarction, known severe renal failure 
(patients undergoing dialysis or with a creatinine level >350 μmol/L), 
nephrotic syndrome, hepatic failure or other causes of hypo-
albuminaemia.
Case definition and data collection
The diagnosis of HF was based on the standard case definition as 
described in THESUS-HF.[5] The diagnosis of HF was made on 
finding the clinical syndrome of effort intolerance (i.e. shortness of 
breath, dyspnoea and/or fatigue) associated with features of fluid 
retention (i.e. peripheral oedema, orthopnoea, paroxysmal nocturnal 
dyspnoea, raised jugular venous pressure, pulmonary oedema and/
or tender hepatomegaly) in the presence of clinical signs of cardiac 
dysfunction (i.e. low blood pressure, displaced apex, presence of third 
heart sound). The presence of cardiac dysfunction was confirmed by 
echocardiography performed by a trained echocardiographer. The 
cause of HF was based on information obtained from the history, 
physical examination, echocardiography, and special aetiological 
investigations interpreted by the admitting team on the index 
admission. Where no cause for HF was stated, the research team 
determined the aetiology from the given data.
For this study, consecutive patients enrolled into the GSH 
THESUS-HF registry from 1 June 2012 to 31 May 2014 (24 months) 
with >90% completed data were selected. The THESUS-HF registry 
holds the basic clinical information as determined by the clinical 
history and previous medical records, along with an echocardiogram 
report confirming the diagnosis of HF. Furthermore, patients were 
followed up for 180 days to document their clinical outcomes of 
rehospitalisation and death. Their baseline demographic and clinical 
information, echocardiographic findings, treatment and clinical 
outcomes were entered onto a data capture sheet by the research 
nurse and echocardiographer. Outstanding demographic, clinical, 
treatment and outcomes data were collected through folder review, 
pharmacy records and telephonic consultations with the study 
participants. All completed data capture sheets were entered into the 
THESUS-HF database.
Statistical analysis
Data were analysed using the Statistical Package for the Social 
Sciences (SPSS) version 23 (IBM, USA) and ROOT.[12] Normally 
distributed continuous data are presented as means with standard 
deviations (SDs), and non-Gaussian distributed variables as medians 
plus ranges. Categorical data are presented as percentages. The case 
fatality rate was calculated at discharge and at 6 months of follow-up.
Ethical considerations
The University of Cape Town Human Research Ethics Committee 
granted ethics approval for this study (ref. no. 579/2014). All patients 
entered into the THESUS-HF registry gave written informed consent.
Results
Baseline patient characteristics on admission
One hundred and twenty patients were enrolled in the THESUS-HF 
registry at GSH between 1 June 2012 and 31 May 2014. One patient 
was excluded owing to missing clinical details. Table 1 shows the 
baseline clinical characteristics for the total cohort (N=119) and 
compares the incident cases (first presentations) with the prevalent 
cases (recurrent presentations). The mean (SD) age of the cohort was 
49.9 (16.3) years. Sixty-nine patients (57.5%) were female, and the 
main population groups were black African (n=59, 49.6%) and mixed 
ancestry (n=54, 45.4%).
The prevalent cases were more likely to be people of mixed ancestry, 
and this group had more hypertension, DM, hyperlipidaemia, IHD, 
pericardial disease and cardiomyopathy and higher New York Heart 
Association (NYHA) functional class than incident cases.
Causes of HF
The main causes of HF were cardiomyopathy (n=24, 20.2%), IHD 
(n=23, 19.3%) and valvular heart disease (n=22, 18.5%). Hyper-
tension accounted for 10.1% (n=12) of the cohort. Owing to 
the small sample size, cardiomyopathy represents the cumulative 
causes of cardiomyopathy, and includes peripartum cardiomyopathy, 
idiopathic dilated cardiomyopathy and HIV cardiomyopathy. Fig. 1 
shows the causes of HF.
Therapies for HF: Admission and discharge/day 7 
admission
Intravenous (IV) loop diuretics were the most commonly used 
IV therapy on admission (n=94, 79.0%), while renin-angiotensin 
system blockers were the most commonly used oral treatment 
(n=70, 59.3%). Mechanical ventilation and dobutamine were used 
in only 0.9% (n=1) and 1.7% (n=2) of cases, respectively. Renin-
angiotensin system blockers (73.0%, n=81), loop diuretics (74.6%, 
n=82) and beta-blockers (42.7%, n=47) were most commonly issued 
on discharge. On discharge only 26.1% of patients (n=15) received 
aldosterone antagonists and 15.5% (n=17) digoxin. IV dopamine, IV 
digoxin and oral hydralazine were never prescribed. Table 2 shows 
the IV and oral therapies used in incident and prevalent cases.
Length of stay, rehospitalisation and case fatality rate
The mean (SD) length of stay in hospital for all cases was 9.2 (12.2) 
days, with a median of 6 days (range 1 - 109). Rehospitalisation 
within 180 days occurred in 25.2% (n=30) of the total cohort. Twelve 
patients (10.1%) were lost to follow-up. The main reason for this 
was no reply to telephonic calls (n=11), and one patient moved to 
another province. The rate of death during hospital admission was 
8.4% (10/119 patients), and the case fatality rate at 6 months was 
26.1% (31/119 patients).
Discussion
The main findings of this study include a relatively young population 
suffering from HF, with prevalent cases more likely to have DM, 
hypertension, IHD and more advanced disease. Furthermore, 
cardiomyopathy, IHD and RHD account for the majority of causes 
of HF. There was under-use of beta-blockers, aldosterone antagonists 
and digoxin. Finally, rehospitalisation and case fatality rates were 
high.
The mean age of patients with AHF was 49.9 years, and 58.0% were 
female. These findings are similar to what has been observed in other 
registries from SSA.[4,5,13,14] This is significant, as it demonstrates that 
HF in Cape Town affects the breadwinner generation, rather than 
the elderly as has been noted in the developed world. In contrast, the 
average age of patients with AHF in Europe and North America is 
70 years.[2,3]
There was also a difference in clinical characteristics between 
patients with new-onset disease and those with a previous diagnosis 
of HF. The patients with prevalent disease were mostly from the 
mixed-ancestry community. This may be representative of Cape 
Town’s population demographics, the mixed-ancestry community 
constituting the largest group in the Western Cape.[15] Furthermore, 
patients with prevalent disease had more hypertension, DM, 
hyperlipidaemia and IHD. Comparison of coronary artery disease 
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Table 1. Baseline clinical characteristics of 119 patients with AHF at GSH, Cape Town, SA
Characteristics All cases (N=119) Incident cases (N=89) Prevalent cases (N=30) p-value
Age (yr), mean (SD) 49.9 (16.3) 48.6 (16.2) 53.7 (16.4) 0.143
Sex, n (%) 0.349
Female 69 (58.0) 53 (59.6) 16 (53.3)
Male 50 (42.0) 36 (40.4) 14 (46.7)
Race, n (%) 0.005
Black 59 (49.6) 51 (57.3) 8 (26.7)
White 4 (3.4) 3 (3.4) 1 (3.3)
Mixed ancestry 54 (45.4) 35 (39.3) 19 (63.3)
Asian 2 (1.7) 0 2 (6.7)
AHF admissions in past 12 months, n (%) n/a
0 89 (74.8) 89 (100)
1 22 (18.5) 22 (73.3)
2 4 (3.4) 4 (13.3)
3 4 (3.4) 4 (13.3)
Hypertension, n (%) 58 (48.7) 37 (41.6) 21 (70.0) 0.006
DM, n (%) 26 (21.8) 15 (16.9) 11 (36.7) 0.025
Smoking, n (%) 46 (38.7) 31 (34.8) 15 (50) 0.105
Hyperlipidaemia, n (%) 13 (10.9) 3 (3.4) 10 (33.3) <0.001
IHD, n (%) 17 (14.3) 6 (6.7) 11 (36.7) <0.001
Atrial fibrillation, n (%) 6 (5.0) 5 (5.6) 1 (3.3) 0.526
Stroke, n (%) 5 (4.2) 3 (3.4) 2 (6.7) 0.372
Pericardial disease, n (%) 3 (2.5) 0 3 (10.0) 0.015
RHD, n (%) 12 (10.1) 10 (11.2) 2 (6.7) 0.374
Cardiomyopathy, n (%) 11 (9.2) 4 (4.5) 7 (23.3) 0.005
Cor pulmonale, n (%) 7 (5.9) 3 (3.4) 4 (13.3) 0.066
HIV, n (%) 14 (11.8) 10 (11.2) 4 (13.3) 0.490
PVD, n (%) 2 (1.7) 2 (2.2) 0 0.558
NYHA, n (%) <0.001
I 23 (23.7) 23 (34.3) 0
II 20 (20.6) 17 (25.4) 3 (10.0)
III 44 (45.4) 24 (35.8) 20 (66.7)
IV 10 (10.3) 3 (4.5) 7 (23.3)
BMI (kg/m2), mean (SD) 27.4 (9.8) 27.6 (10.5) 26.7 (7.6) 0.680
Systolic BP (mmHg), mean (SD) 134.6 (33.2) 137.4 (32.9) 126.3 (33.3) 0.115
Diastolic BP (mmHg), mean (SD) 81.9 (22.5) 82.4 (23.3) 80.5 (20.1) 0.688
Heart rate (bpm), mean (SD) 102.5 (22.7) 102.7 (24.3) 101.9 (17.3) 0.865
Respiratory rate (/min), mean (SD) 22.8 (5.3) 23.0 (5.7) 22.0 (3.5) 0.370
Oedema, n (%) 0.762
0 37 (31.1) 27 (30.3) 10 (33.3)
1+ 1 (0.8) 1 (1.1) 0
2+ 21 (17.6) 17 (19.1) 4 (13.3)
3+ 60 (50.4) 44 (49.4) 16 (53.3)
Pulmonary oedema, n (%) 0.038
0 46 (38.7) 33 (37.1) 13 (43.3)
1 4 (3.4) 2 (2.2) 2 (6.7)
2 28 (23.5) 26 (29.2) 2 (6.7)
3 41 (34.5) 28 (31.5) 13 (43.3)
LVEF (%), mean (SD) 34.1 (16.9) 35.9 (17.4) 28.2 (14.0) 0.085
Creatinine (μmol/dL), mean (SD) 109.7 (75.4) 110.2 (83.9) 108.4 (43.5) 0.912
Urea (mmol/L), mean (SD) 10.2 (7.5) 9.7 (7.2) 11.6 (8.3) 0.250
Sodium (mmol/L), mean (SD) 136.9 (6.3) 137.0 (6.6) 136.9 (5.7) 0.943
Haemoglobin (g/dL), mean (SD) 12.3 (2.6) 12.1 (2.7) 12.7 (2.4) 0.329
White cell count (× 109/L), mean (SD) 9.7 (4.5) 9.8 (4.5) 9.2 (4.5) 0.482
AHF = acute heart failure; GSH = Groote Schuur Hospital; SA = South Africa; SD = standard deviation; DM = diabetes mellitus; IHD = ischaemic heart disease; RHD = rheumatic valvular heart 
disease; PVD = peripheral vascular disease; NYHA = New York Heart Association class; BMI = body mass index; BP = blood pressure; bpm = beats per minute; LVEF = left ventricular ejection 
fraction; n/a = not applicable.
Oedema: 0 = complete absence of skin indentation with mild digital pressure in all dependent areas, 1+ = indentation of skin that resolves over 10 - 15 s, 2+ = indentation of skin easily created 
with limited pressure and disappears slowly (≥15 - 30 s), 3+ = large areas of indentation easily produced and slow to resolve (>30 s).
Pulmonary oedema: 0 = no rales heard after clearing cough, 1 = moist or dry rales heard in lower third of one or both lung fields that persist after cough, 2 = moist or dry rales heard throughout 
the lower half to two-thirds of one or both lungs, 3 = moist or dry rales heard throughout both lung fields.
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risk factors in the present study with those of other HF studies in 
SSA shows a greater burden of DM and smoking (Table 3). Finally, 
their baseline NYHA functional class was higher, possibly indicating 
a group of patients with more advanced HF, which may reflect 
suboptimal treatment of HF along with poor follow-up and education 
regarding HF.
In SSA, hypertension, RHD and the endemic cardiomyopathies 
account for the majority of HF cases.[5] In this study, cardiomyopathy, 
IHD and RHD were the leading causes of AHF in Cape Town, 
accounting for 60% of cases referred to tertiary care. Of interest is 
the high prevalence of IHD. Observational studies from SSA report 
the incidence of IHD as a cause of HF to be 0.4 - 9%.[4,5,13,14] In this 
study, 19.3% of patients were diagnosed with an ischaemic cause of 
HF. One of the possible reasons for the disparity in observations may 
be the effects of urbanisation. It has been shown that movement of 
people from rural areas to urban centres results in a change in diet 
and lifestyle, predisposing to the development of IHD.[7,8] Another 
reason may be that a specialist cardiology service was available to 
this study cohort, which may have allowed for better diagnostic 
tests (angiography and echocardiography), resulting in increased 
diagnosis of IHD. Hypertensive HF was less prevalent in this study 
than in other series from SSA. The reason for this is not clear, and 
requires further investigation.
The rate of beta-blocker use was low at discharge in this study 
(42.7%) compared with EHFS II (61%), but was similar to rates of 
use observed in the Tanzania Heart Failure (TaHeF) study (42%) and 
THESUS-HF (50%).[3,5,14] The low rate of beta-blocker use may be due 
to the severity of HF treated. In this cohort, over half of the patients 
presented with NYHA functional classes III and IV combined. On 
discharge, 26.1% of patients received aldosterone antagonists and 
15.5% received digoxin. This is considerably lower than has been 
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Fig. 1. Causes of heart failure. (‘Other’ includes toxins, arrhythmias and 
Graves’ disease.)
Table 2. Prescribed medication on admission and discharge or day 7 admission
Treatment
All cases Incident cases Prevalent cases
Admission, n (%)
Discharge/d 7, 
n (%) Admission, n (%)
Discharge/d 7, 
n (%) Admission, n (%)
Discharge/d 7, 
n (%)
Nitrates (IV) 4 (3.5) 0 3 (3.5) 0 1 (3.3) 0
Furosemide (IV) 94 (79.0) 20 (18.0) 71 (79.8) 13 (15.9) 23 (76.7) 7 (24.1)
Dobutamine 2 (1.7) 0 2 (2.4) 0 0 0
Mechanical ventilation 1 (0.9) 0 0 0 1 (3.3) 0
ACE inhibitor/ARB 70 (59.3) 81 (73.0) 48 (54.5) 57 (69.5) 22 (73.3) 24 (82.8)
Loop diuretics 24 (20.7) 82 (74.6) 17 (19.8) 60 (74.1) 7 (23.3) 22 (75.9)
Beta-blockers 21 (18.3) 47 (42.7) 13 (15.3) 32 (39.5) 8 (26.7) 15 (51.7)
Digoxin 15 (13.2) 17 (15.5) 9 (10.6) 12 (14.8) 6 (20.7) 5 (17.2)
Nitrates 4 (3.5) 9 (8.2) 3 (3.5) 4 (4.9) 1 (3.3) 5 (17.2)
Aldosterone 
antagonists
15 (12.9) 29 (26.1) 9 (10.5) 19 (23.2) 6 (20.0) 10 (34.5)
Simvastatin 36 (30.8) 36 (32.4) 21 (24.1) 21 (25.6) 15 (50.0) 15 (51.7)
Aspirin 30 (25.6) 32 (28.8) 19 (21.8) 19 (23.2) 11 (36.7) 13 (44.8)
All anticoagulation* 45 (38.5) 32 (28.8) 32 (36.8) 26 (31.7) 13 (43.3) 6 (20.7)
IV = intravenous; ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker.
*Warfarin, heparin, enoxaparin.
Table 3. Comparison of CAD risk factors in the present study with HF studies from SSA and other parts of the world
Study, country Diabetes (%) Hypertension (%) Smoking (%)
Current study 21.8 48.7 38.7
Stewart et al.,[4] SA 10 55 48
Lokker et al.,[18] SA 24 70 NR
Mwita et al.,[19] Botswana 15.5 54.9 NR
Ogah et al.,[13] Nigeria 10 64.3 3.3
Makubi et al.,[14] Tanzania 12 45 NR
THESUS-HF[5] 11.1 55 9.8
EHFS II,[3] Europe 62.5 32.8 NR
ADHERE,[2] USA 44 73 NR
CAD = coronary artery disease; HF = heart failure; SSA = sub-Saharan Africa; SA = South Africa; THESUS-HF = The Sub-Saharan Africa Survey of Heart Failure; EFHS II = EuroHeart Failure 
Survey II; ADHERE = Acute Decompensated Heart Failure National Registry; CAD = Coronary Artery Disease; NR = not reported.
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described in the rest of SSA, where aldosterone and digoxin are 
prescribed in 60 - 75% and 31 - 72% of cases, respectively.[4,5,13,14] The 
side-effect profiles, potential drug interactions and close monitoring of 
these therapies in a population group where compliance to follow-up 
and access to specialist care is suboptimal may explain their limited 
use. Hydralazine use was low, possibly because of its limited availability 
at GSH and also its known low use by physicians in SSA. [5] In this 
study, 28.8% of patients were discharged on aspirin. This is a far lower 
figure than is described in THESUS-HF, where >50% of patients were 
discharged on aspirin despite the low prevalence of ischaemic HF.[5] 
This study shows a population with a high prevalence of IHD. Whether 
the use of aspirin in this study is in keeping with the prevalence of IHD 
as identified in this cohort needs to be evaluated further.
The mean length of stay of 9.2 days is similar to the number of 
admission days described in studies from developed nations and 
SSA.[3-5,13] The 6-month readmission rate was 25.2%. The reasons 
for this high readmission rate may be three-fold. First, suboptimal 
adherence to evidence-based treatments may be resulting in high 
readmission rates. Second, gaps in patients’ understanding of HF 
and the importance of treatment follow-up and lifestyle adherence 
may be a further contributory factor.[16] Finally, hospital bed pressure 
may lead to premature discharge of HF patients. The in-hospital and 
6-month mortality rates were 8.4% and 26.1%, respectively. This is 
higher than is described in the rest of SSA. THESUS-HF, the largest 
multicentre study on HF to date, reported an in-hospital mortality 
rate of 4.2% and a 6-month mortality rate of 17.8%.[5] These high 
mortality rates may be due to the different aetiological pattern in 
Cape Town, with a significant contribution of IHD and a lower 
prevalence of hypertension as the primary cause of AHF. There was 
also low use of life-saving medications such as beta-blockers and 
aldosterone inhibitors. These observations stress the importance 
of adhering to evidence-based treatment guidelines. Furthermore, 
the management of HF is complex and requires a multidisciplinary 
approach encompassing routine follow-up with patient education, 
optimisation of treatment and social support.[17]
Study limitations
This study has a number of limitations. The sample size was small and 
may under-represent the causes of HF. A second limitation was that 
rehospitalisation to other institutions may not have been documented 
in all cases. Furthermore, only admission and discharge treatment 
practices are described. It may be that the use of aldosterone and 
beta-blockers as well as other HF treatment increased during 
ambulatory care in the community. There is also lack of data on 
dosages of drugs that confer survival benefit in HF. Finally, 10.1% of 
the patient cohort was lost to follow-up, which may have contributed 
to under-estimation of the case fatality rate.
Conclusion
This study provides important insights into the demographics, 
causes, treatment and outcomes of AHF in Cape Town. It confirms 
observations in earlier SSA HF studies that a young adult population 
is affected by HF. Cardiomyopathy, IHD and RHD account for 60% 
of cases of AHF. However, of concern is the high prevalence of IHD 
in this cohort, the highest reported so far in SSA. Furthermore, there 
was serious under-use of beta-blockers, aldosterone antagonists and 
digoxin. The high readmission rate and 6-month mortality rate may 
reflect suboptimal adherence to evidence-based treatment guidelines. 
There needs to be emphasis on the rigorous application of treatment 
guidelines to reduce readmission and mortality associated with AHF 
in Cape Town.
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